MARKET

CRBU

CRBU

Caribou Biosciences, Inc.
NASDAQ
1.980
+0.260
+15.12%
Opening 09:35 03/31 EDT
OPEN
1.800
PREV CLOSE
1.720
HIGH
1.980
LOW
1.800
VOLUME
328.35K
TURNOVER
--
52 WEEK HIGH
3.535
52 WEEK LOW
0.6600
MARKET CAP
191.34M
P/E (TTM)
-1.2483
1D
5D
1M
3M
1Y
5Y
1D
Caribou rises on FDA RMAT designation for CAR-T therapy
Seeking Alpha · 3h ago
BUZZ-Caribou rises on FDA's regenerative medicine advanced therapy tag for blood cancer therapy
Reuters · 3h ago
Caribou CB-011 granted Regenerative Medicine Advanced Therapy designation
TipRanks · 3h ago
Caribou Biosciences Receives FDA's Regenerative Medicine Advanced Therapy Designation To CB-011 For Relapsed Or Refractory Multiple Myeloma
Benzinga · 3h ago
CARIBOU BIOSCIENCES ANNOUNCES THE FDA GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION TO CB-011, AN ALLOGENEIC ANTI-BCMA CAR-T CELL THERAPY
Reuters · 3h ago
Weekly Report: what happened at CRBU last week (0323-0327)?
Weekly Report · 1d ago
Weekly Report: what happened at CRBU last week (0316-0320)?
Weekly Report · 03/23 10:00
Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value
Seeking Alpha · 03/17 13:38
More
About CRBU
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.

Webull offers Caribou Biosciences Inc stock information, including NASDAQ: CRBU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRBU stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRBU stock methods without spending real money on the virtual paper trading platform.